Human immunodeficiency virus type I-specific CD8+T cell subset abnormalities in chronic infection persist through effective antiretroviral therapy

Table 2 General characteristics and changes for subjects with detectable HIV replication

ID	Duration of infection	^aVL zenith	^bCD4 nadir	^cVL study course	^dCD4_i	CD4_f	^eMonths study course	^fCD8⁺ IFNγ⁺ CD45RA⁺ _i	CD8⁺ IFNγ⁺ CD45RA⁺ _f
11	>15 yrs	>5.88	63	4.58	308	335	60	15%	16%
17	>15 yrs	4.48	296	4.12	518	490	30	ND	ND
35	>15 yrs	4.77	176	3.37	660	736	48	35%	12%
39	>15 yrs	5.64	24	2.70	754	961	30	6%	14%
51	>15 yrs	5.61	40	3.29	390	297	36	33%	25%
57	>15 yrs	5.48	176	4.25	420	506	36	14%	8%
77	>15 yrs	5.00	207	3.80	692	288	24	ND	ND
78	>15 yrs	>5.88	32	4.53	110	184	36	24%	23%
85	>14 yrs	4.60	307	2.65	684	663	66	11%	11%
98	>13 yrs	5.73	69	3.79	484	435	48	ND	ND
116	>12 yrs	5.56	44	3.22	319	378	48	23%	23%
125	>12 yrs	5.06	59	4.52	496	209	42	31%	ND
187	>7 yrs	3.93	1064	2.89	1127	1419	36	37%	ND
195	>5 yrs	4.93	462	4.54	518	462	24	27%	25%
209	>5 yrs	4.97	500	4.72	812	500	24	ND	ND

^aThe highest recorded virus load (VL) for each subject in log₁₀ copies HIV RNA/mL plasma.
^bThe lowest recorded peripheral blood CD4⁺ T lymphocyte count for each subject.
^cVirus load (log₁₀ copies HIV RNA/mL plasma) averaged over the 4 time points for each subject.
^dThe number of CD4⁺ T lymphocytes/μL peripheral blood for each subject at beginning (CD4_i) and end (CD4_f) of period over which HIV-specific CD8⁺ T cell responses were assessed.
^eTotal time period over which four assessments of HIV-specific CD8⁺ T cell responses occurred.
^fPercentage of HIV-specific CD8⁺ T cells producing INF-γ that expressed CD45RA at beginning (_i) and end (_f) of period over which HIV-specific CD8⁺ T cell responses were assessed.

ISSN: 1471-2334